MRNA:NSD-Moderna, Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 419.05

Change

+32.54 (+8.42)%

Market Cap

USD 155.19B

Volume

0.03B

Avg Analyst Target

USD 203.38 (-51.47%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Moderna, Inc., a biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases. As of March 9, 2021, the company had 13 programs in clinical trials and a total of 24 development programs in six modalities comprising prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted and cell surface therapeutics, and systemic intracellular therapeutics. The company has strategic alliances with AstraZeneca PLC, Merck & Co., Inc., Vertex Pharmaceuticals Incorporated, Vertex Pharmaceuticals (Europe) Limited, the Biomedical Advanced Research and Development Authority, the Defense Advanced Research Projects Agency, the National Institute of Allergy and Infectious Diseases, the National Institutes of Health, the Coalition for Epidemic Preparedness Innovations, and Bill & Melinda Gates Foundation. Moderna, Inc. also has collaborations with Lonza Ltd. for the manufacture of COVID-19 vaccine; and Catalent Inc., Laboratorios Farmacéuticos Rovi, S.A., Recipharm, and Lonza Group for fill-finish manufacturing of its COVID-19 vaccine candidate, as well as Aldevron, LLC for supporting COVID-19 vaccine and additional programs in company's clinical development pipeline. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Company Website : http://www.modernatx.com

Address : 200 Technology Square, Cambridge, MA, United States, 02139

Employees : 1,300

Fiscal Year End : December

Currency: USD

Country : USA

Technical Indicators

Beta : 1.47

52 Week High : 386.94

Short Ratio : 1.71

52 Week Low : 54.21

Shorted Shares : 12,463,613

200 Day Moving Average : 185.58

Shorted Shares Previous Month : 14,329,025

50 Day Moving Average : 261.96

Shares Held By Insiders : 9.68%

Short Percentage : 3.00%

Shares Held by Institutions : 54.53%

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-08-04 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
BNTX BioNTech SE

+62.63 (+17.80%)

 USD79.30B 59.35 50.07
REGN Regeneron Pharmaceuticals, Inc

-5.56 (-0.95%)

 USD62.49B 16.70 12.83
VRTX Vertex Pharmaceuticals Incorpo..

-0.46 (-0.23%)

 USD51.84B 26.37 17.81
ALXN Alexion Pharmaceuticals, Inc

N/A

 USD40.34B 59.23 42.56
BGNE BeiGene, Ltd

+1.64 (+0.48%)

 USD31.54B N/A N/A
GMAB Genmab A/S

+0.11 (+0.24%)

 USD29.62B 33.28 3.77
SGEN Seagen Inc

+5.02 (+3.17%)

 USD28.78B 49.36 38.34
RPRX Royalty Pharma plc

-0.94 (-2.49%)

 USD22.88B 31.06 13.91
ALNY Alnylam Pharmaceuticals, Inc

+4.63 (+2.59%)

 USD21.02B N/A N/A
IMMU Immunomedics, Inc

N/A

 USD20.31B N/A N/A

ETFs Containing MRNA

Symbol Name Weight Mer Price(Change) Market Cap
BBH VanEck Vectors Biotech ET.. 0.00 % 0.35 %

+5.86 (+2.77%)

 USD0.57B
BTEK:LSE iShares IV Public Limited.. 0.00 % 0.35 %

+0.17 (+3.19%)

 USD0.48B
MXDU Nationwide Maximum Divers.. 0.00 % 0.34 %

+0.02 (+0.06%)

 USD0.12B
RBUS Nationwide Risk-Based U.S.. 0.00 % 0.30 %

-0.22 (-0.55%)

 USD0.12B
ZHU:CA BMO Equal Weight US Healt.. 0.00 % 0.39 %

+0.97 (+2.11%)

 USD0.05B
HWF:CA Middlefield Healthcare & .. 0.00 % 1.45 %

N/A

 USD0.05B
IDNA iShares Genomics Immunolo.. 0.00 % 0.47 %

+1.42 (+2.78%)

 USD0.33B
BTEC:LSE iShares Nasdaq US Biotech.. 0.00 % 0.35 %

+0.24 (+3.28%)

 USD0.48B
BTEE:LSE iShares Nasdaq US Biotech.. 0.00 % 0.35 %

+0.24 (+3.24%)

 USD0.04B
ZUH:CA BMO Equal Weight US Healt.. 0.00 % 0.39 %

+0.53 (+0.62%)

 USD0.57B
FEX:LSE First Trust Global Funds .. 0.00 % 0.75 %

+11.92 (+0.24%)

 USD0.06B
FEXD:LSE First Trust Global Funds .. 0.00 % 0.75 %

+17.50 (+0.38%)

 USD0.04B
FEXU:LSE First Trust Global Funds .. 0.00 % 0.75 %

N/A

 USD0.06B
XRMU:LSE Xtrackers (IE) Public Lim.. 0.00 % 0.35 %

+0.11 (+0.30%)

 USD0.14B
XRSM:F Xtrackers (IE) Public Lim.. 0.00 % 0.35 %

+0.12 (+0.38%)

 USD0.14B
2B70:XETRA iShares Nasdaq US Biotech.. 0.00 % 0.35 %

+0.21 (+3.36%)

 USD0.40B
FTGU:XETRA First Trust Global Funds .. 0.00 % 0.75 %

+0.31 (+0.53%)

 USD0.06B
ULVM VictoryShares USAA MSCI U.. 0.00 % 0.20 %

-0.46 (-0.69%)

 USD0.44B
VXF Vanguard Extended Market .. 0.00 % 0.06 %

-1.03 (-0.55%)

 USD114.53B
BBP ETFis Series Trust I - Vi.. 0.00 % 0.79 %

+0.64 (+1.26%)

 USD0.03B
FLAG FLAG-Forensic Accounting .. 0.00 % 1.44 %

N/A

 USD4.83M
BIB ProShares Ultra Nasdaq Bi.. 0.00 % 0.95 %

+2.88 (+2.83%)

 USD0.27B
BTAL AGFiQ U.S. Market Neutral.. 0.00 % 2.19 %

+0.05 (+0.29%)

 USD0.10B
EUSA iShares MSCI USA Equal We.. 0.00 % 0.15 %

-0.36 (-0.42%)

 USD0.45B
FAD First Trust Multi Cap Gro.. 0.00 % 0.63 %

+0.13 (+0.11%)

 USD0.22B
FBT First Trust NYSE Arca Bio.. 0.00 % 0.55 %

+2.55 (+1.49%)

 USD1.96B
FEX First Trust Large Cap Cor.. 0.00 % 0.59 %

-0.28 (-0.32%)

 USD1.19B
FHH:CA First Trust AlphaDEX U.S... 0.00 % 0.77 %

N/A

 USD0.02B
FTC First Trust Large Cap Gro.. 0.00 % 0.60 %

+0.84 (+0.74%)

 USD1.19B
TUSA First Trust Total US Mark.. 0.00 % 0.70 %

-0.29 (-0.59%)

 USD0.02B
FXH First Trust Health Care A.. 0.00 % 0.61 %

+0.87 (+0.71%)

 USD1.52B
IBB iShares Biotechnology ETF 0.00 % 0.46 %

+2.75 (+1.62%)

 USD10.82B
MUS:CA Mackenzie Maximum Diversi.. 0.00 % 0.50 %

+0.06 (+0.16%)

 USD0.20B
MWD:CA Mackenzie Maximum Diversi.. 0.00 % 0.55 %

N/A

 USD0.48B
QQEW First Trust NASDAQ-100 Eq.. 0.00 % 0.58 %

+0.07 (+0.06%)

 USD1.28B
QQQE Direxion NASDAQ-100 Equal.. 0.00 % 0.35 %

+0.10 (+0.12%)

 USD0.38B
QQXT First Trust NASDAQ-100 Ex.. 0.00 % 0.60 %

-0.27 (-0.30%)

 USD0.15B
XRSM:XETRA Xtrackers (IE) Public Lim.. 0.00 % 0.35 %

+0.08 (+0.24%)

 USD0.14B

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)		 Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 301.12% 98% A+ 99% A+
Dividend Return N/A N/A N/A N/A N/A
Total Return 301.12% 98% A+ 99% A+
Trailing 12 Months  
Capital Gain 452.84% 98% A+ 98% A+
Dividend Return N/A N/A N/A N/A N/A
Total Return 452.84% 98% A+ 98% A+
Trailing 5 Years  
Capital Gain N/A 100% A+ 100% A+
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A 100% A+ 100% A+
Average Annual (5 Year Horizon)  
Capital Gain 861.15% 99% A+ 99% A+
Dividend Return N/A N/A N/A N/A N/A
Total Return 861.15% 99% A+ 99% A+
Risk Return Profile  
Volatility (Standard Deviation) 1,016.27% 2% F 2% F
Risk Adjusted Return 84.74% 96% A 89% B+
Market Capitalization 155.19B 100% A+ 99% A+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)		 Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 259.06 6% F 6% F
Price/Book Ratio 36.99 4% F 3% F
Price / Cash Flow Ratio 76.56 2% F 6% F
EV/EBITDA 194.72 3% F 6% F
Management Effectiveness  
Return on Equity 21.83% 96% A 89% B+
Return on Invested Capital -40.99% 58% F 19% F
Return on Assets 5.37% 94% A 82% B-
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 1.71 72% C- 63% D
Short Percent 3.99% 67% D+ 44% F
Beta 1.47 44% F 30% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Discussions

New Post

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters then its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector